Published in Sci Transl Med on November 04, 2009
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol (2010) 4.62
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med (2011) 2.56
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet (2011) 2.13
Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest (2011) 1.62
Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet (2011) 1.44
Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness. Nat Med (2013) 1.20
Targeting RNA splicing for disease therapy. Wiley Interdiscip Rev RNA (2013) 1.17
A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2. Hum Mol Genet (2010) 1.15
Assays for the identification and prioritization of drug candidates for spinal muscular atrophy. Assay Drug Dev Technol (2014) 1.13
Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late. PLoS One (2010) 1.11
The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet (2013) 1.09
Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One (2012) 1.08
Alternative splicing and retinal degeneration. Clin Genet (2013) 0.98
Phosphatidylserine increases IKBKAP levels in familial dysautonomia cells. PLoS One (2010) 0.98
Splicing regulation of the survival motor neuron genes and implications for treatment of spinal muscular atrophy. Front Biosci (Landmark Ed) (2010) 0.96
Mouse models of SMA: tools for disease characterization and therapeutic development. Hum Genet (2012) 0.96
Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study. PLoS One (2012) 0.95
Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta (2013) 0.93
A multi-exon-skipping detection assay reveals surprising diversity of splice isoforms of spinal muscular atrophy genes. PLoS One (2012) 0.92
Discovery, synthesis, and biological evaluation of novel SMN protein modulators. J Med Chem (2011) 0.91
New therapeutic approaches to spinal muscular atrophy. Curr Neurol Neurosci Rep (2012) 0.91
SMN-inducing compounds for the treatment of spinal muscular atrophy. Future Med Chem (2012) 0.90
RNA-binding proteins in neurodegenerative disease: TDP-43 and beyond. Wiley Interdiscip Rev RNA (2011) 0.90
Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy. RNA Biol (2010) 0.89
Spinal Muscular Atrophy Therapeutics: Where do we Stand? Neurotherapeutics (2015) 0.86
Evaluation of peripheral blood mononuclear cell processing and analysis for Survival Motor Neuron protein. PLoS One (2012) 0.85
Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol Med (2013) 0.84
Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses. PLoS One (2011) 0.84
Targeting SR proteins improves SMN expression in spinal muscular atrophy cells. PLoS One (2014) 0.83
RNA-Binding Proteins: Splicing Factors and Disease. Biomolecules (2015) 0.80
Exonic mutations in the SLC12A3 gene cause exon skipping and premature termination in Gitelman syndrome. J Am Soc Nephrol (2014) 0.79
Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy. Neurotherapeutics (2013) 0.78
Splicing-factor alterations in cancers. RNA (2016) 0.78
Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides. PLoS One (2016) 0.77
ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight (2016) 0.76
Identification and characterization of a spinal muscular atrophy-determining gene. Cell (1995) 17.41
The spliceosome: design principles of a dynamic RNP machine. Cell (2009) 12.82
Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev (2001) 9.14
Pre-mRNA splicing: awash in a sea of proteins. Mol Cell (2003) 8.28
RNA and disease. Cell (2009) 7.98
A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A (1999) 7.60
Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet (1997) 6.08
The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet (2000) 5.38
A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet (2001) 5.02
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol (2007) 4.95
The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet (1997) 4.86
A novel nuclear structure containing the survival of motor neurons protein. EMBO J (1996) 4.72
Pre-mRNA splicing in the new millennium. Curr Opin Cell Biol (2001) 4.64
Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet (2001) 4.50
A mouse model for spinal muscular atrophy. Nat Genet (2000) 4.37
Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol (2007) 3.97
Control of alternative RNA splicing and gene expression by eukaryotic riboswitches. Nature (2007) 3.87
A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet (2003) 3.84
Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol (2003) 3.75
International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul Disord (1992) 3.26
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet (2008) 3.24
Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest (2007) 3.11
Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci U S A (2000) 2.72
Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet (2003) 2.51
Riboswitch RNAs: using RNA to sense cellular metabolism. Genes Dev (2008) 2.47
Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol (2006) 2.41
Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol (2007) 2.29
Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet (2005) 2.29
Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol (2003) 2.28
Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med (2002) 2.26
Riboswitch control of gene expression in plants by splicing and alternative 3' end processing of mRNAs. Plant Cell (2007) 2.18
The spinal muscular atrophy disease gene product, SMN: A link between snRNP biogenesis and the Cajal (coiled) body. J Cell Biol (1999) 2.17
INHIBITION OF PROTEIN SYNTHESIS BY CHLORTETRACYCLINE IN THE E. COLI IN VITRO SYSTEM. Proc Natl Acad Sci U S A (1965) 2.16
hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1. Hum Mol Genet (2002) 1.84
Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res (2006) 1.84
Serine/arginine-rich protein-dependent suppression of exon skipping by exonic splicing enhancers. Proc Natl Acad Sci U S A (2005) 1.83
Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet (2001) 1.80
A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet (1998) 1.77
Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep (2007) 1.77
Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One (2009) 1.67
Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet (2006) 1.62
Therapeutics development for spinal muscular atrophy. NeuroRx (2006) 1.62
Deciphering the assembly pathway of Sm-class U snRNPs. FEBS Lett (2008) 1.55
Targeting RNA with small-molecule drugs: therapeutic promise and chemical challenges. Acc Chem Res (2001) 1.55
SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2 beta 1. Hum Mol Genet (2002) 1.53
Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet (2005) 1.52
Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1. Eur J Hum Genet (2003) 1.48
Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol (2004) 1.45
Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc Natl Acad Sci U S A (2005) 1.45
Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res (2001) 1.42
The molecular bases of spinal muscular atrophy. Curr Opin Genet Dev (2002) 1.38
Substances that can change alternative splice-site selection. Biochem Soc Trans (2008) 1.34
Alternative splicing: a new drug target of the post-genome era. Biochim Biophys Acta (2005) 1.30
Animal models of spinal muscular atrophy. Hum Mol Genet (2000) 1.30
The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2) gene. Mol Cell Biol (2008) 1.27
Tetracycline aptamer-controlled regulation of pre-mRNA splicing in yeast. Nucleic Acids Res (2007) 1.24
The spliceosome: a novel multi-faceted target for therapy. Trends Biochem Sci (2005) 1.18
Teaching TetR to recognize a new inducer. J Mol Biol (2003) 1.17
Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med (Berl) (2007) 1.17
Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation. RNA (2008) 1.16
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet (2007) 1.14
Differential 3' splice site recognition of SMN1 and SMN2 transcripts by U2AF and U2 snRNP. RNA (2009) 0.99
Versatile and facile synthesis of diverse semisynthetic tetracycline derivatives via Pd-catalyzed reactions. J Org Chem (2003) 0.98
Inhibition of nuclear pre-mRNA splicing by antibiotics in vitro. Eur J Biochem (2002) 0.84
Phase I trial of aclacinomycin A. Cancer Treat Rep (1982) 0.78
Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet (2002) 16.29
ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res (2003) 12.81
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet (2002) 5.80
An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet (2006) 4.56
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2. Genes Dev (2008) 4.24
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature (2011) 4.04
Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol (2003) 3.75
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov (2012) 3.70
Comprehensive splice-site analysis using comparative genomics. Nucleic Acids Res (2006) 3.30
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet (2008) 3.24
The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A (2010) 3.08
SR proteins function in coupling RNAP II transcription to pre-mRNA splicing. Mol Cell (2007) 3.04
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev (2010) 3.02
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med (2011) 2.56
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS (2010) 2.51
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol (2008) 2.38
Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol (2007) 2.29
Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet (2005) 2.29
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem (2004) 2.26
Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma. J Clin Oncol (2013) 2.25
Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics (2008) 2.24
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ (2012) 2.23
HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS (2003) 2.15
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS (2009) 2.15
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Nuclear export and retention signals in the RS domain of SR proteins. Mol Cell Biol (2002) 2.04
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol (2007) 1.96
Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury. Am J Respir Crit Care Med (2011) 1.92
Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr (2007) 1.89
The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol (2012) 1.88
Involvement of SR proteins in mRNA surveillance. Mol Cell (2004) 1.84
Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol (2003) 1.84
The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med (2012) 1.81
BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet (2002) 1.80
SF2/ASF autoregulation involves multiple layers of post-transcriptional and translational control. Nat Struct Mol Biol (2010) 1.78
A rational nomenclature for serine/arginine-rich protein splicing factors (SR proteins). Genes Dev (2010) 1.77
Aberrant 5' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res (2007) 1.71
Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood (2009) 1.71
A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet (2009) 1.70
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect (2008) 1.70
Distribution of SR protein exonic splicing enhancer motifs in human protein-coding genes. Nucleic Acids Res (2005) 1.70
Determinants of the inherent strength of human 5' splice sites. RNA (2005) 1.69
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS (2006) 1.68
Intrinsic differences between authentic and cryptic 5' splice sites. Nucleic Acids Res (2003) 1.66
Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc Natl Acad Sci U S A (2005) 1.65
HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr (2004) 1.64
Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS (2006) 1.57
BRCA1 promotes induction of ssDNA by ionizing radiation. Cancer Res (2006) 1.55
A splicing-independent function of SF2/ASF in microRNA processing. Mol Cell (2010) 1.55
Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med (2007) 1.54
hnRNP A1 associates with telomere ends and stimulates telomerase activity. RNA (2006) 1.50
Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet (2007) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing. J Biol Chem (2002) 1.50
Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood (2011) 1.46
RNA landscape of evolution for optimal exon and intron discrimination. Proc Natl Acad Sci U S A (2008) 1.45
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr (2004) 1.42
The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci U S A (2008) 1.42
Interaction between the RNA binding domains of Ser-Arg splicing factor 1 and U1-70K snRNP protein determines early spliceosome assembly. Proc Natl Acad Sci U S A (2011) 1.42
An exonic splicing enhancer in human IGF-I pre-mRNA mediates recognition of alternative exon 5 by the serine-arginine protein splicing factor-2/alternative splicing factor. Endocrinology (2002) 1.42
SpliceTrap: a method to quantify alternative splicing under single cellular conditions. Bioinformatics (2011) 1.42
OLego: fast and sensitive mapping of spliced mRNA-Seq reads using small seeds. Nucleic Acids Res (2013) 1.41
Pick one, but be quick: 5' splice sites and the problems of too many choices. Genes Dev (2013) 1.39
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One (2011) 1.38
Cooperative-binding and splicing-repressive properties of hnRNP A1. Mol Cell Biol (2009) 1.37
Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep (2012) 1.36
Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum Mutat (2004) 1.35
A novel histone exchange factor, protein phosphatase 2Cgamma, mediates the exchange and dephosphorylation of H2A-H2B. J Cell Biol (2006) 1.34
A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol (2010) 1.34
HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS (2008) 1.34
Factors associated with misdiagnosis of COPD in primary care. Prim Care Respir J (2011) 1.34
An LKB1 AT-AC intron mutation causes Peutz-Jeghers syndrome via splicing at noncanonical cryptic splice sites. Nat Struct Mol Biol (2004) 1.33
Intravitreal triamcinolone acetonide for diabetic macular edema. Retina (2005) 1.33
A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet (2006) 1.32
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med (2005) 1.31
Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol Cell (2011) 1.28
Control of pre-mRNA splicing by the general splicing factors PUF60 and U2AF(65). PLoS One (2007) 1.28
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS (2013) 1.28
Diagnosing rupture of membranes using combination monoclonal/polyclonal immunologic protein detection. J Reprod Med (2013) 1.27
Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood (2004) 1.26
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br J Clin Pharmacol (2005) 1.26
Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol (2012) 1.25
Splicing remodels messenger ribonucleoprotein architecture via eIF4A3-dependent and -independent recruitment of exon junction complex components. Proc Natl Acad Sci U S A (2007) 1.24
Regulation of cerebral cortex size and folding by expansion of basal progenitors. EMBO J (2013) 1.24
Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nat Chem Biol (2012) 1.22
Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol Cell Proteomics (2010) 1.22
Alternative splicing regulation by interaction of phosphatase PP2Cgamma with nucleic acid-binding protein YB-1. Nat Struct Mol Biol (2007) 1.21
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther (2007) 1.20